Molecular imaging of prostate cancer
- 30 June 2009
- journal article
- review article
- Published by Elsevier BV in Methods
- Vol. 48 (2), 193-199
- https://doi.org/10.1016/j.ymeth.2009.03.021
Abstract
Prostate carcinoma is the most common non-cutaneous malignancy in males. Imaging of prostatic lesions is of great importance and aids in oncologic management and monitoring of therapy response. Particularly molecular imaging based on positron emission tomography (PET) and single photon emission computerized tomography (SPECT) has great potential. Using radio-labelled molecular probes, these approaches are highly sensitive and can provide key molecular and functional information on tumours. The identification of suitable targets based on unique genetic and biochemical features of cancer lesions is one of the core activities driving progress in molecular imaging of pathological processes. Nowadays, mainly metabolic probes are being used routinely for detection and staging of prostate cancer. The development of new specific receptor ligands and targeted probes and antibodies holds great promise to further enhance the performance of molecular imaging and to further improve the diagnosis and monitoring of prostate cancer.Keywords
This publication has 76 references indexed in Scilit:
- RNA Editing of Androgen Receptor Gene Transcripts in Prostate Cancer CellsPublished by Elsevier BV ,2008
- Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out viewNuclear Medicine and Biology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- DU‐145 and PC‐3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulationFEBS Letters, 2006
- The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer ProgressionEuropean Urology, 2006
- Androgen receptor modifications in prostate cancer cells upon long‐termandrogen ablation and antiandrogen treatmentInternational Journal of Cancer, 2005
- Workgroup 3: Transgenic and reconstitution models of prostate cancerThe Prostate, 1998
- Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID miceNature Medicine, 1997
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Isolation of a human prostate carcinoma cell line (DU 145)International Journal of Cancer, 1978